Macular Degeneration Treatment Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI4306
Macular Degeneration Treatment size is expected to grow significantly from 2019 to 2025.
Increased incidence and prevalence of retinal disorders, elevated annual therapy costs for pipeline drugs, increased geriatric population, enhanced health care infrastructure are some of the key factors propelling the growth of the macular degeneration treatment market. According to the American Academy of Ophthalmology, in the U.S. the age-related macular degeneration (AMD) is the major cause of severe central visual insight loss in people over the age of 50. Thus, the high prevalence of the disease is expected to enhance treatment adoption, which is further anticipated to boost the market growth.
The growing awareness programs, the introduction of new therapies is also expected to drive the worldwide market for macular degeneration therapy over the forecast period. Furthermore, developed countries, such as Germany, Japan, U.S, France, Canada, and Australia offer huge opportunities for the macular degeneration treatment market. This is due to favorable reimbursement policies, large base of patients, and high expenditure on healthcare. Moreover, an increase in R&D investments by companies operating in the market to develop innovative products for the treatment of macular degeneration diseases is anticipated to propel the growth of the market globally. However, the increase in off-label use and lack of awareness for macular degeneration are some of the factors that may hamper the growth of the macular degeneration treatment market.
Wet age-related macular degeneration (wAMD) is accounts for significant market share in the macular degeneration treatment market. The large number of ongoing researches to treat wet age-related macular degeneration are some of the prominent factors propelling the growth of the segment in the global market. Moreover, favorable reimbursement policies in the developed region are expected to boost the growth of the segment in the global market.
The anti-vascular endothelial growth factor (anti-VEGFs) segment should witness significant growth in the macular degeneration treatment market during the forecast period. The anti-VEGFs are gold standard treatment for macular degeneration. The new drug developments in this drug class for instance introduction of long-acting anti-VEGF is anticipated to boost the growth of the segment in the global market.
The hospital segment is estimated to hold major share in the macular degeneration treatment market in 2018. A large population favors to visit hospitals for treatment of severe eye diseases, as they are well equipped, and due to the quality of care provided. Moreover, the cost of treatment at hospitals is low that is also expected to spur the growth of the segment in the market.
North America's macular degeneration treatment market accounts significant revenue share in 2018 and will grow substantially during the forecast period. The high adoption of drugs for macular degeneration treatments in North America along with a large patient pool is expected to propel the growth of the region. Furthermore, increasing geriatric population, high government support, increased awareness about macular degeneration treatment, in the region will spur the regional growth.
Some of the major players operating in the macular degeneration treatment industry include Novartis, GlaxoSmithKline, Bayer, Ophthotech Corporation, Neurotech Pharmaceuticals, StemCells, F. Hoffmann-La Roche, Sanofi, Pfizer, Santen Pharmaceuticals, Valeant Pharmaceuticals, and Allergan. The market for macular degeneration therapy is defined by a large number of acquisitions and partnerships, an increase in the number of product launches and growing dominance of the leading players. For instance, in April 2019, the Novartis has announced the acceptance of biological license application for brolucizumab, by U.S. FDA for the treatment of wet age-related macular degeneration. The company also announced the launch of the drug by 2019 end. The new drug introduction for the treatment of macular degeneration is expected to generate immense opportunity for the growth of the market globally.
Macular Degeneration Treatment Market By Disease Indication, 2014-2025 (USD Million)
- Dry Age-related Macular Degeneration (dAMD)
- Wet Age-related Macular Degeneration (wAMD)
Macular Degeneration Treatment Market By Drug Class, 2014-2025 (USD Million)
- Anti-vascular Endothelial Growth Factor (VEGFs)
Macular Degeneration Treatment Market By Distribution Channel, 2014-2025 (USD Million)
- Ophthalmic Clinics
- Ambulatory Surgical Centers
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Ophthotech Corporation
- Neurotech Pharmaceuticals
- F. Hoffmann-La Roche
- Santen Pharmaceuticals
- Valeant Pharmaceuticals
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability